Emilia Genini

ORCID: 0000-0002-6884-0028
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cytomegalovirus and herpesvirus research
  • Herpesvirus Infections and Treatments
  • Parvovirus B19 Infection Studies
  • HIV Research and Treatment
  • Respiratory viral infections research
  • Acute Myeloid Leukemia Research
  • Pregnancy and preeclampsia studies
  • Genomic variations and chromosomal abnormalities
  • Advanced biosensing and bioanalysis techniques
  • HIV/AIDS drug development and treatment
  • Cancer Genomics and Diagnostics
  • Organ and Tissue Transplantation Research
  • Animal Virus Infections Studies
  • Biosensors and Analytical Detection
  • SARS-CoV-2 and COVID-19 Research
  • Chronic Myeloid Leukemia Treatments
  • Neurogenetic and Muscular Disorders Research
  • Viral gastroenteritis research and epidemiology
  • MicroRNA in disease regulation
  • Toxoplasma gondii Research Studies
  • Gestational Diabetes Research and Management
  • Congenital Diaphragmatic Hernia Studies
  • Transplantation: Methods and Outcomes
  • RNA Interference and Gene Delivery
  • Neonatal and Maternal Infections

Istituti di Ricovero e Cura a Carattere Scientifico
1997-2014

Policlinico San Matteo Fondazione
1997-2014

University of Pavia
1998-2005

University of Milan
2001

Primary human cytomegalovirus (HCMV) infections during pregnancy are associated with a high risk of virus transmission to the fetus. To identify correlates intrauterine HCMV transmission, serial serum samples from transmitter and non-transmitter pregnant women primary infection were analyzed for presence neutralizing antibodies against different glycoproteins glycoprotein complexes, which known mediate entry into distinct types host cells. Neutralizing activity was detected in sera early...

10.1371/journal.pone.0059863 article EN cc-by PLoS ONE 2013-03-29

ABSTRACT Using a recently developed model for in vitro generation of pp65-positive polymorphonuclear leukocytes (PMNLs), we demonstrated that PMNLs from immunocompetent subjects may harbor both infectious human cytomegalovirus (HCMV) and viral products (pp65, p72, DNA, immediate-early [IE] pp67 late mRNAs) as early 60 min after coculture with umbilical vein endothelial cells (HUVEC) or embryonic lung fibroblasts (HELF) infected clinical HCMV isolate (VR6110) other wild-type strains. The...

10.1128/jvi.74.12.5629-5638.2000 article EN Journal of Virology 2000-06-15

Four human cytomegalovirus (HCMV) isolates from different clinical sources were extensively propagated in embryonic lung fibroblasts (HELF). Plaque each of the four virus strains evaluated for their ability to be transferred polymorphonuclear leukocytes (PMNL) and grow endothelial cells (EC). While all found both PMNL- EC-tropic, variants identified that lacked biological properties, while three parental lost transfer capacity before passage 50 HELF. It was demonstrated one field (VR6110)...

10.1099/0022-1317-82-6-1429 article EN Journal of General Virology 2001-06-01

The T cell-mediated immune response to human cytomegalovirus (HCMV) after primary infection, as well the determinants of intrauterine transmission, are poorly understood.Sequential peripheral blood leukocyte samples from 74 pregnant women and 29 nonpregnant individuals with infection were examined for HCMV-specific CD4+ cells by cytokine flow cytometry (CFC) lymphoproliferative (LPR) analysis. Immunological results 19 transmitter 21 nontransmitter mothers compared.Comparison CFC LPR analysis...

10.1086/498872 article EN The Journal of Infectious Diseases 2005-12-16

To measure the red cell distribution width (RDW) ranges at birth and to evaluate potential association with typical neonatal diseases: patent of ductus arteriousus (PDA), bronchopulmonary dysplasia (BPD), late-onset sepsis (LOS) mortality.Forty-six full-term, 41 preterm, 35 intrauterine growth restricted (IUGR) infants participated in this retrospective, observational study. RDW was measured before 3 days life (T0) all infants, first month (T1) preterm/IURG patients.RDW% mean (standard...

10.1179/1607845413y.0000000141 article EN Hematology 2013-11-13

Problem To target gestational diabetes mellitus (GDM) by means of temporal variation in pregnancy‐associated plasma protein A (PAPP‐A) and soluble human leukocyte antigen‐G (sHLA‐G). Method study Retrospective analysis PAPP‐A sHLA‐G blood levels historical samples 112 GDM controls, drawn at first trimester, prospective 18 105 controls collected triplicate along the pregnancy. Six hundred sixty‐five were analyzed. Results Gestational had significantly lower first‐trimester concentrations than...

10.1111/aji.12270 article EN American Journal of Reproductive Immunology 2014-05-23

Objective: To investigate the lymphoproliferative response (LPR) to human cytomegalovirus (HCMV) in two groups of AIDS patients undergoing long-term highly active antiretroviral therapy (HAART): group 1 (n = 22) with nadir CD4+ T cell count <50/μl and no HCMV disease; 2 16) T-cell disease. All had previously undergone monotherapy or dual before initiating HAART. Study Design Methods: The were tested prospectively for count, HIV RNA load, viremia, LPR at baseline, then after 3 4 years A...

10.1097/00126334-200112010-00003 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2001-12-01

ABSTRACT Evaluation of human cytomegalovirus (HCMV)-specific T-helper immunity could contribute in optimizing anti-HCMV therapy immunodeficiency virus (HIV)-infected patients. Testin the lymphoproliferative response (LPR) is standard technique used to evaluate response, but its use routine diagnostic laboratory setting can be problematic. The most promising new alternative determination HCMV-specific CD4 + T-cell frequency by flow cytometry detection intracellular cytokine production after...

10.1128/cdli.8.6.1225-1230.2001 article EN Clinical and Diagnostic Laboratory Immunology 2001-11-01

Objective: To investigate the lymphoproliferative response (LPR) to human cytomegalovirus (HCMV) in two groups of AIDS patients undergoing long-term highly active antiretroviral therapy (HAART): group 1 (n = 22) with nadir CD4+ T cell count <50/μl and no HCMV disease; 2 16) T-cell disease. All had previously undergone monotherapy or dual before initiating HAART. Study Design Methods: The were tested prospectively for count, HIV RNA load, viremia, LPR at baseline, then after 3 4 years A...

10.1097/00042560-200112010-00003 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2001-12-01
Coming Soon ...